Trial Profile

Intermediate Expanded Access Protocol With CNM-Au8 for Multiple Sclerosis

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CNM Au8 (Primary)
Indications Multiple sclerosis
Focus Expanded access; Therapeutic Use
Sponsors Clene Nanomedicine

Most Recent Events

23 Jul 2024 Secondary identifier and indication for the study has been changed.
22 Feb 2024 According to a Clene Nanomedicine media release, Dr. Cudkowicz is the principal investigator.
22 Feb 2024 Results of pooled analysis of survival analysis of expanded access programs of two trials (EAP01 & EAP02) were presented in a Clene Nanomedicine Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com